Marianna Silletta

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance.

Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance.

Journal: Frontiers in oncology

Published: June 22, 2026

Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score.

Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 13, 2026

Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.

Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.

Journal: Breast cancer research and treatment

Published: November 07, 2025

Role and Characteristic of Multidisciplinarity in Hepatocellular Carcinoma Management and Care Pathway Certification: Bottom-Up Approach of the MDT Project in Italy.

Role and Characteristic of Multidisciplinarity in Hepatocellular Carcinoma Management and Care Pathway Certification: Bottom-Up Approach of the MDT Project in Italy.

Journal: Oncology and therapy

Published: September 18, 2025

Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting.

Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting.

Journal: Targeted oncology

Published: June 03, 2025

Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.

Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.

Journal: JHEP reports : innovation in hepatology

Published: May 06, 2025

Patient-Reported Outcome Measurement and Reporting for Patients with Soft Tissue Tumors: A Scoping Literature Review.

Patient-Reported Outcome Measurement and Reporting for Patients with Soft Tissue Tumors: A Scoping Literature Review.

Journal: Cancers

Published: April 29, 2025

Lenvatinib Is Highly Effective in Patients with Hepatocellular Carcinoma Related to Both Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Etiology: A Propensity Score Analysis.

Lenvatinib Is Highly Effective in Patients with Hepatocellular Carcinoma Related to Both Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Etiology: A Propensity Score Analysis.

Journal: Cancers

Published: April 08, 2025

Intermediate hepatocellular carcinoma: new horizons and prospects for our patients.

Intermediate hepatocellular carcinoma: new horizons and prospects for our patients.

Journal: Expert review of gastroenterology & hepatology

Published: November 01, 2024

The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.

The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.

Journal: The Lancet. Digital health

Published: October 01, 2024

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Journal: JAMA oncology

Published: July 18, 2024

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab.

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab.

Journal: JHEP reports : innovation in hepatology

Published: March 14, 2024

Showing 1-12 of 53

Last Updated: 09/26/2026